Skip to main content
Download PDF
  • Primary research
  • Open access
  • Published:

Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p/ADAM17 axis in colorectal cancer cells

Cancer Cell International volume 20, Article number: 473 (2020) Cite this article

Abstract

Background

Colorectal cancer (CRC) is one of the most general malignant tumors. Accumulating evidence implied that long non-coding RNA Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) participated in the tumorigenesis of CRC. However, the effect of MALAT1 in drug-resistance needed to be further illustrated.

Methods

Levels of MALAT1, microRNA (miR)-324-3p, and a disintegrin and metalloprotease metallopeptidase domain 17 (ADAM17) were detected using quantitative real-time polymerase chain reaction (qRT-PCR) or western blot assay. Cell Counting Kit 8 (CCK-8) was used to assess the half maximal inhibitory concentration (IC50) of oxaliplatin (Ox). Meanwhile, cell proliferation, migration and apoptosis were detected by CCK-8, transwell assay, and flow cytometry, respectively. The interaction between miR-324-3p and MALAT1 or ADAM17 was clarified by dual-luciferase reporter assay. Also, the effect of MALAT1 on tumor growth was detected in xenograft tumor mice treated with Ox.

Results

Significant up regulation of MALAT1 and ADAM17, and decrease of miR-324-3p were observed in Ox-resistant CRC tissues and cells. MALAT1 deficiency enhanced the sensitivity of Ox-resistant CRC cells response to Ox, while miR-324-3p repression or ADAM17 acceleration could overturn this effect. Moreover, MALAT1 silencing repressed tumor growth in Ox-treated nude mice. Mechanically, MALAT1 exerted promotion effect on the resistance response to Ox via miR-324-3p/ADAM17 axis in Ox-resistant CRC cells.

Conclusion

MALAT1 modulated the sensitivity of Ox through ADAM17 in Ox-resistant CRC cells by sponging miR-324-3p, thus MALAT1 might serve as a novel insight for the therapy of CRC.

Highlights

  1. 1.

    MALAT1 and ADAM17 were highly expressed, while miR-324-3p was down regulated in Ox-resistant CRC tissues and cells.

  2. 2.

    Knockdown of MALAT1 could boost the sensitivity of Ox-resistant CRC cells response to Ox.

  3. 3.

    Either miR-324-3p inhibition or ADAM17 increase could abolish the effect of MALAT1 deletion on Ox-sensitivity in vitro.

  4. 4.

    MALAT1 regulated the tumorigenesis via miR-324-3p/ADAM17 axis in Ox-treated mice.

Background

Colorectal cancer (CRC) is one of the leading causes which contributed to cancer-related deaths, and more than 1.2 million new cases of CRC are diagnosed every year all over the world [1, 2]. Recently, oxaliplatin (Ox)-based chemotherapy was identified as one of the most common therapeutic strategies after surgical resection [3]. Ox combines with 5-fluorouracil and leucovorin (FOLFOX), and this combination can promote the drug-response rate (over than 50%) and improve the median survival for the metastatic CRC [4]. However, the outcomes of metastasis and chemoresistance after receiving chemotherapy are the master barrier to the efficiency of CRC therapy [5]. Investigating the potential mechanism and finding therapeutic biomarkers are necessary to develop the drug-therapies for CRC patients.

Long non-coding RNAs (lncRNAs) with over than 200 nucleotides can exert the functional effects by modifying and interacting numerous types of genes and proteins through mountainous mechanisms [6, 7], flowed by participating in the fundamental pathogenesis, such as carcinogenesis and cardiovascular diseases [8,9,10]. The function of lncRNAs in cancer progression attracted extensive attentions over the past decades, numerous lncRNAs were identified to be implicated in carcinogenesis by working as oncogenic or tumor suppressor genes [11]. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a well-known lncRNA, which is strikingly up regulated in liver cancer and cervical cancer [12, 13] and acts vital roles in the development of human cancers and chemoresistance [14, 15]. In CRC, MALAT1 can contribute to the tumor development via releasing oncogene polypyrimidine tract binding protein [16]. Also, MALAT1 has been reported to reduce the Ox-sensitivity, thereby decreasing the therapeutic effect via repressing miR-218 [17]. Thus, it was necessary to completely understand the function of MALAT1 in the Ox-resistance response of CRC cells.

Recently, miRNAs are regarded as a class of non-coding RNAs, and it can partially complement with messenger RNA (mRNA), thereby curbing the expression of targeted proteins [18]. Previously, several miRNAs have been confirmed to be involved in the pathogenesis of human cancers [19]. Emerging researches also suggested that miRNAs were strictly related to chemoresistance in diverse cancers [20]. Moreover, growing number of miRNAs were identified to be associated with the processes of CRC. For instance, miR-324-3p was a key regulator in the radioresistance of nasopharyngeal carcinoma by targeting oncogene WTN2B [21, 22]. In this study, we aimed to explore whether miR-324-3p could account for the Ox-sensitivity in CRC. Furthermore, A disintegrin and metalloprotease (ADAM) metallopeptidase domain 17, a member of ADAMs family, was demonstrated to be related to the drug-resistance in CRC.

In the paper, we focused on the expression of MALAT1, miR-324-3p, and ADAM17 in Ox-resistant CRC tissues and cells. Moreover, we highlighted the potential mechanisms of MALAT1 in modifying the sensitivity of Ox-resistant CRC cells response to Ox.

Materials and methods

Clinical specimens and cell treatment

Ox-resistant CRC patients (n = 40) and Ox-sensitive CRC patients (n = 40) were recruited from Linyi Cancer Hospital. And the CRC specimens were received from each participator. Tumor response was verified in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Besides, written informed consents were gained from all participators based on the guidelines authorized by the Ethics Committee of Linyi Cancer Hospital.

For cell culture, the CRC cell lines (HCT116 and HCT8) and human fetal normal colonic cells (FHC) were purchased from American Tissue Culture Collection (Manassas, VA, USA). HCT116 and HCT8 were maintained in McCoy’s 5A medium (Hyclone, Logan, UT, USA) and Roswell Park Memorial Institute-1640 (RPMI-1640; Hyclone), respectively. FHC were cultured with dulbecco’s modified eagle medium/F12 (DMEM/F12; Hyclone). All the mediums were supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA), penicillin–streptomycin (Gibco; 100 U/mL penicillin and 100 mg/mL streptomycin) at 37 °C in 5% CO2 and 95% Moist air.

Development of Ox-resistant cell lines

This protocol was referenced from the previous descriptions [3]. Briefly, HCT116 and HCT8 cells were cultured in relative media with the addition of 0.1 μmol/L oxaliplatin (Ox; Selleck Chemicals, HOU, USA). The surviving cells were grown and passaged twice (over 9 days) to measure viability. Then, the survival cells were exposed in the complete medium with 0.5 μmol/L (15 days), 1.0 μmol/L (30 days), and finally to 2 μmol/L. The Ox-resistant CRC cell lines were named as HCT116/OxR and HCT8/OxR.

Cell transfection

Specific short hairpin (shRNA) targeting MALAT1 (sh-MALAT1) and its negative control (sh-NC) were synthesized in RiboBio (Guangzhou, China). The full-length of ADAM17 was inserted into pcDNA3.1 to create overexpression vector (ADAM17), and the scrambled sequence was cloned into pcDNA3.1, thereby generating over expression control (pcDNA). Besides, the miR-324-3p mimic (miR-324-3p), miR-324-3p inhibitor (anti-miR-324-3p) and their controls (miR-NC and anti-miR-NC) were obtained from HANBIO (Shanghai, China). The relative sequences were respectively transfected into HCT116/OxR and HCT8/OxR cells using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA). Moreover, sh-MALAT1 or sh-NC with lentiviral vector was used to form Ox-resistant CRC cells stably.

Quantitative real-time polymerase chain reaction (qRT-PCR) assay

The total RNA from tumor Ox-resistant CRC tissues and cells was extracted with Trizol reagent (Invitrogen). The total RNA was reversely transcribed into complementary DNA (cDNA) utilizing PrimeScript RT reagent Kit (Takara, Dalian, China). Then, qRT-PCR was carried out with the synthesized cDNA, corresponding primers, and the reagent of SYBR Prime Script RT-PCR Kits (Takara). The levels were calculated using the 2−ΔΔCt method. U6 small nuclear 1 (U6, Gene ID: 26827) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GeneID: 2597) were used to standardize the expression of miR-324-3p (Gene ID: 442898), MALAT1 (GeneID: 378938) and ADAM17 (GeneID: 6868). The primers were as listed: MALAT1 (Forward: 5′-GGGTGTTTACGTAGACCAGAACC-3′, Reverse: 5′-CTTCCAAAAGCCTTCTGCCTTAG-3′); miR-324-3p (Forward: 5′-ACTGCCCCAGGTGCTGCTGG-3′, Reverse: 5′-TGTCAAAAGGGAAATGAGGC-3′); ADAM17 (Forward: 5′-GTGCAGGGTCCGAGGT-3′, Reverse: 5′-GCGAGCACAGAATTAATACGAC-3′); GAPDH (Forward: 5′-GCACCGTCAAGGCTGAGAAC-3′, Reverse: 5′-ATGGTGGTGAAGACGCCAGT-3′); U6 (Forward: 5′-CTCGCTTCGGCAGCACA-3′, Reverse: 5′-AACGCTTCACGAATTTGCGT-3′).

Cell Counting Kit 8 (CCK-8)

The cells were seeded in a 96-well plate and cultured for 72 h with different dose of Ox. Then, 10 mg/mL of CCK8 reagent was added, and cell viability was detected on the base of the protocols. The absorbance at 450 nm was measured using a microplate reader. The half-maximal inhibitory concentration (IC50) of Ox was determined in HCT116/OxR and HCT8/OxR cells.

Transwell assay

For the detection of cell migration in CRC, cells cultured in the serum-free medium were seeded on the upper chamber (Corning Incorporated, Big Flats, NY, USA) pre-coated with Matrigel (BD Biosciences, San Jose, CA, USA). The lower chamber supplemented with DMEM containing 10% FBS was used as a chemoattractant. After incubation for 24 h at 37 °C, the migrated cells were fixed, stained, and counted using a microscope (Nikon Eclipse TS100; Nikon, Tokyo, Japan).

Flow cytometry assay

HCT116/OxR and HCT8/OxR cells were cultured in McCoy’s 5A or RPMI-1640 contained 10% FBS with 2 μmol/L Ox, respectively. After incubation for 48 h, cells were digested using trypsin (Gibco) and washed using Phosphate Buffer solution (PBS; Hyclone). Then, these cells were incubated with Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) reagent (Vazyme, Nanjing, China). The apoptotic signals were analyzed using flow cytometer.

Dual-luciferase reporter assay

StarBase v3.0 was used to predict the binding sites between MALAT1 and miR-324-3p, and the complementary sequences between miR-324-3p and the 3′ Untranslated Regions (3′UTR) of ADAM17 were predicted by Target Scan7.2. The common fragments between miR-324-3p and MALAT1 or ADAM17 were cloned and inserted into pmirGLO (Promega, Madison, WI, USA), forming WT-MALAT1 and ADAM17-WT. Similarly, the relative mutants (MUT-MALAT1 and ADAM17-MUT) were constructed in the same way. The reporters were co-transfected with miR-324-3p or miR-NC, respectively., Finally, the luciferase activity was evaluated through adopting a Dual-Luciferase Reporter Assay System kit (Promega).

Western blot assay

Western blot analysis was performed as previously described [23]. Briefly, protein was extracted and loaded on a 10% polyacrylamide gel. Then, proteins were transferred onto Polyvinylidene Fluoride (PVDF; Millipore, Bedford, MA, USA), and incubated with primary antibody including ADAM17 (ab2051, 1:1000, Abcam, Cambridge, MA, USA), Bcl-2 (ab182858, 1:2000, Abcam), Cleaved caspase-3 (ab2302, 1:1000, Abcam), E-cadherin (14472, 1:1000, Cell signaling technology, Boston, MA, USA), Vimentin (5741, 1:1000, 5741, Cell signaling technology) and GAPDH (ab8245, 1:6000, Abcam) overnight at 4 °C. GAPDH was used as a internal control. Then, the membranes were incubated with secondary antibody (Abcam) for 40 min at temperature, and an enhanced chemiluminescent substrate kit (Millipore) was employed to visualize the unique proteins.

Xenograft tumor model

The male nude BALB/c mice (n = 6/group) at the age of 6 weeks with 16–20 g weight were purchased from Vital River Laboratory Animal Technology (Beijing, China). This experiment was performed according to the guidelines of the National Animal Care and Ethics Institution and approved by the Animal Research Committee of Linyi Cancer Hospital. Firstly, the mice were randomly divided into three groups, and HCT116/OxR cells (lentivirus-mediated sh-MALAT1 or sh-NC) with 200 µL PBS were subcutaneously injected into the left flank of the mice. Ox (5 mg/kg) was administered two times every week with intragastric injection. After injection for 1 week, the tumor length and width were measured and recorded every 4 days for total 6 times. The volume was calculated according to the formula: volume = length × width2 × 0.5. All mice were sacrificed, the xenograft tumors were fetched and weighed.

Statistical analysis

Data were exhibited as the mean ± standard deviation (SD). Statistical analysis was performed using Student’s t-test (two-group) and one-way analysis of variance (three or more groups) followed by turkey’s test. P < 0.05 was deemed statistically significant.

Results

MALAT1 was up regulated in Ox-resistant CRC tissues and cells

This study recruited Ox-resistant CRC patients (n = 40) and Ox-sensitive CRC patients (n = 40) from Linyi Cancer Hospital and the detailed information of these patients was shown in Table 1. To explore the role of MALAT1 in CRC, we detected the expression of MALAT1 in Ox-resistant CRC tissues and cells. As described in Fig. 1a–c, MALAT1 was highly expressed in Ox-resistant CRC tissues (Fig. 1a) and cells (Fig. 1b, c). Subsequently, we determined the IC50 values of oxaliplatin in both CRC and Ox-resistant CRC cells and found that the IC50 values of oxaliplatin was significantly increased in Ox-resistant CRC cells compared with CRC cells (Fig. 1d). These data indicated that MALAT1 played a crucial role in Ox-resistant CRC.

Table 1 Demographic characteristics and clinicopathologic features of colorectal cancer patients (n = 80)
Full size table
Fig. 1
figure 1

The level of MALAT1 was up regulated in Ox-resistant CRC tissues and cells. a QRT-PCR analysis for the level of MALAT1 in Ox-resistant CRC tissues (n = 40) and Ox-sensitive CRC tissues (n = 40). b, c The expression of MALAT1 in Ox-resistant CRC (HCT116/OxR and HCT8/OxR), CRC (HCT116 and HCT8) and normal cells (FHC). c The IC50 value of Ox in HCT116, HCT116/OxR, HCT8 and HCT8/OxR was detected by CCK-8 assay. *P < 0.05

Full size image

Knockdown of MALAT1 could augment Ox-sensitivity in HCT116/OxR and HCT8/OxR cells

Firstly, we determined the transfection efficiency of sh-MALAT1 and found the high knockdown efficiency of sh-MALAT1 (Fig. 2a). CCK8 assay manifested that MALAT1 deletion repressed the IC50 values of oxaliplatin (Fig. 2b) and cell proliferation (Fig. 2c) in both HCT116/OxR and HCT8/OxR cells. Moreover, a distinct decrease of cell migration was observed in MALAT1-silenced HCT116/OxR and HCT8/OxR cells (Fig. 2f, g). Also, we examined the effect of MALAT1 silencing on cell apoptosis, flow cytometry indicated that MALAT1 deletion potently triggered cell apoptosis in HCT116/OxR and HCT8/OxR cells (Fig. 2h). Meanwhile, we detected the expression of apoptosis related protein Bcl-2 and Cleaved caspase-3, as well as epithelial to mesenchymal transition (EMT)-related proteins E-cadherin and Vimentin. Our data indicated that MALAT1 down regulation significantly decreased the expression of Bcl-2, Cleaved caspase-3 and Vimentin but increased E-cadherin expression (Fig. 2i and j). Taken together, the deficiency of MALAT1 increased the sensitivity of HCT116 and HCT8 cells to oxaliplatin.

Fig. 2
figure 2

Knockdown of MALAT1 could augment the sensitivity response to Ox in HCT116/OxR and HCT8/OxR cells. a–j HCT116/OxR and HCT8/OxR cells were transfected with sh-NC or sh-MALAT1. a The knockdown efficiency of sh-MALAT1 in HCT116/OxR and HCT8/OxR cells. b, c The detection of IC50 value of Ox in HCT116/OxR and HCT8/OxR cells. d, e Measurement of cell viability by CCK-8 assay. f, g Measurement of cell migration HCT116/OxR and HCT8/OxR cells by transwell assay. h Determination of cell apoptosis in HCT116/OxR and HCT8/OxR cells by flow cytometry. i, j The expression of Bcl-2, Cleaved caspase-3, E-cadherin and Vimentin was detected by western blot. N = 3, *P < 0.05

Full size image

MiR-324-3p inhibitor overturned the repressive influence of MALAT1 silencing on the Ox-resistance of HCT116/OxR and HCT8/OxR cells

The possible miRNAs targets to MALAT1 were predicted by StarBase. There were four miRNAs (miR-5691, miR-1913, miR-324-3p, miR-670-3p) which were predicted to have potential binding sites of MALAT1. Dual-luciferase reporter assay were used to assess the regulatory relationships between these miRNAs and MALAT1. As shown in Additional file 1: Fig. S1A, these miRNAs were negatively regulated by MALAT1, and the negative regulatory relationship between MALAT1 and miR-324-3p was more obvious than the others, thus we chose miR-324-3p to investigate further. The complementary binding sequences between miR-324-3p and MALAT1 was shown in Fig. 3a. To confirm the direct interaction between MALAT1 and miR-324-3p, we performed the dual-luciferase reporter assay. The results validated that miR-324-3p could specifically block the fluorescence intensity of WT-MALAT1, whereas the co-transfection with miR-324-3p had no significant impact on the mutant reporter (Fig. 3b and c). The expression of miR-324-3p was decreased in Ox-resistant CRC tissues (Fig. 3d). In addition, an inverse relationship between MALAT1 and miR-324-3p was determined in Ox-resistant CRC tissues (Fig. 3e). Similarly, we found that miR-324-3p was also down regulated in Ox-resistant CRC cells compared with CRC cells (Fig. 3f). Next, the efficiency of anti-miR-324-3p was verified using qRT-PCR, the level of miR-324-3p was reduced by anti-miR-324-3p (Fig. 3g). Besides, our data suggested that the decrease of IC50 induced by MALAT1 deletion was reversed by miR-324-3p inhibitor in Ox-resistant CRC cells (Fig. 3h, i). Moreover, cell proliferation (Fig. 3j, k) and migration (Fig. 3l, m) inhibited by MALAT1 down regulation were blocked by miR-324-3p deletion in Ox-resistant CRC cells (Fig. 3j–m). We also determined cell apoptosis and discovered that MALAT1 deletion induced cell apoptosis was harbored by miR-324-3p deletion (Fig. 3n). Furthermore, we found that the regulatory effects of MALAT1 deletion on the expression of Bcl-2, Cleaved caspase-3, E-cadherin and Vimentin were reversed by miR-324-3p down regulation (Fig. 3o, p). These data meant that MALAT1 exerted regulatory effects on cell proliferation, migration and apoptosis in Ox-resistant CRC cells via sponging miR-324-3p.

Fig. 3
figure 3

MiR-324-3p inhibitor overturned the effects of MALAT1 silencing on HCT116/OxR and HCT8/OxR cells. a The predictive binding sites between MALAT1 and miR-324-3p. b, c Dual-luciferase reporter analysis for the luciferase activities of WT-MALAT1 and MUT-MALAT1 in Ox-resistant CRC cells. d The expression of miR-324-3p in Ox-resistant CRC tissues (n = 40) and Ox-sensitive CRC tissues (n = 40). e The relationship between MALAT1 and miR-324-3p in Ox-resistant CRC tissues (n = 40). f The level of miR-324-3p in Ox-resistant CRC cells, CRC cells and FHT cells. g The transfection efficiency of anti-miR-324-3p in Ox-resistant cells. h–p HCT116/OxR and HCT8/OxR cells were transfected with sh-NC, sh-MALAT1, sh-MALAT1 + anti-miR-NC, or sh-MALAT1 + anti-miR-324-3p. h, i The measurement of IC50 value in HCT116/OxR and HCT8/OxR cells response to Ox. j, k Detection of cell viability by CCK-8 assay. l, m Measurement of cell migration using transwell assay. n Detection of cell apoptosis by flow cytometry. o, p The expression of Bcl-2, Cleaved caspase-3, E-cadherin and Vimentin was determined by western blot. N = 3, *P < 0.05

Full size image

ADAM17 was a target of miR-324-3p

As predicted by TargetScan7.2, there were binding sites between miR-324-3p and ADAM17 (Fig. 4a). There were three genes (ADAM12, ADAM17 and ADAM22) that probably had the existence of binding sites. Dual-luciferase reporter assay were used to assess the regulatory relationships between these genes and miR-324-3p. Then we tested the regulatory relationships between these genes and miR-324-3p, and the results showed that ADAM17 showed more obvious negative regulatory relationship with miR-324-3p. Subsequently, the relationship between miR-324-3p and ADAM17 was illustrated using dual-luciferase reporter assay, the results presented that the luciferase activity of ADAM17-WT was decreased in HCT116/OxR and HCT8/OxR cells co-transfected with miR-324-3p, but miR-324-3p could not alter the luciferase activity of ADAM17-MUT in vitro (Fig. 4b and c). Besides, the mRNA and protein levels of ADAM17 were up regulated in Ox-resistant CRC tissues (Fig. 4d and e). Moreover, we observed an inverse relationship between miR-324-3p and ADAM17 in Ox-resistant CRC tissues (Fig. 4f). Similarly, we also observed the higher mRNA and protein expression of ADAM17 in Ox-resistant CRC cells in comparison to CRC cells (Fig. 4g, h). As shown in Fig. 4i, j, MALAT1 deletion inhibited the expression of ADAM17, which was reversed by miR-324-3p inhibitor. These results suggested that miR-324-3p was a direct target of ADAM17.

Fig. 4
figure 4

ADAM17 was a target of miR-324-3p. a The complementary sequences between miR-324-3p and ADAM17. b, c The fluorescence intensities of ADAM17-WT and ADAM17-MUT in HCT116/OxR and HCT8/OxR cells transfected with miR-324-3p. d, e Measurement of ADAM17 mRNA and protein expression in Ox-resistant CRC tissues (n = 40) and Ox-sensitive CRC tissues (n = 40). f The relationship between miR-324-3p and ADAM17 in Ox-resistant CRC tissues (n = 40). g, h Detection of ADAM17 mRNA and protein expression in Ox-resistant CRC cells, CRC cells, and FHC cells. i, j The protein expression of ADAM17 in HCT116/OxR and HCT8/OxR cells transfected with sh-NC, sh-MALAT1, sh-MALAT1 + miR-NC, or sh-MALAT1 + miR-324-3p. N = 3, *P < 0.05

Full size image

ADAM17 up regulation could abrogate the effect of MALAT1 reduction on the Ox-sensitivity in CRC cells

Next, we investigated whether ADAM17 could modulate Ox-resistance in CRC. Firstly, the over expression vector of ADAM17 was constructed and transfected into HCT116/OxR and HCT8/OxR cells, the mRNA and protein level of ADAM17 were remarkably enhanced in vitro (Fig. 5a and b). CCK8 analysis displayed that the inhibition effect of MALAT1 knockdown on the IC50 of Ox was eliminated by ADAM17 over expression in vitro (Fig. 5c, d). Moreover, the repression of MALAT1 deletion on cell proliferation (Fig. 5e, f) and migration (Fig. 5g, h) was restored by ADAM17 over expression in HCT116/OxR and HCT8/OxR cells. And the promotion of MALAT1 deletion on cell apoptosis was blocked by ADAM17 over expression in HCT116/OxR and HCT8/OxR cells (Fig. 5i). Furthermore, the inhibition on Bcl-2, Cleaved caspase-3 expression and Vimentin and promotion on E-cadherin expression induced by MALAT1 deletion were reversed by ADAM17 over expression (Fig. 5j, k). All the findings revealed that the effect of MALAT1 deletion on Ox-resistance was rescued by ADAM17 over expression in HCT116/OxR and HCT8/OxR cells.

Fig. 5
figure 5

ADAM17 up regulation could abrogate the effect of MALAT1 reduction on the sensitivity of Ox-resistant CRC cells. a, b The transfection efficiency of ADAM17 in Ox-resistant CRC cells. c–k HCT116/OxR and HCT8/OxR cells were transfected with sh-NC, sh-MALAT1, sh-MALAT1 + pcDNA, or sh-MALAT1 + ADAM17. c, d The detection of IC50 value of Ox in HCT116/OxR and HCT8/OxR cells. e, f Measurement of cell viability by CCK-8 assay. g, h Measurement of cell migration HCT116/OxR and HCT8/OxR cells by transwell assay. i Determination of cell apoptosis in HCT116/OxR and HCT8/OxR cells by flow cytometry. j, k The expression of Bcl-2, Cleaved caspase-3, E-cadherin and Vimentin was detected by western blot. N = 3, *P < 0.05

Full size image

MALAT1 silencing promoted Ox-sensitivity in xenograft tumor model

Then, we explored the effects of MALAT1 on tumorigenesis in vivo. After injection for 27 days, the tumor volume and weight were declined by MALAT1 down regulation in Ox-treated mice in comparison with the control (Fig. 6a, b). Moreover, we found that decreased MALAT1 and ADAM17 expression and increased miR-324-3p expression were found in tumor tissues isolated from sh-MALAT1 mice treated with Ox (Fig. 6c). Also, the protein level of ADAM17 was constrained by MALAT1 down regulation in Ox-treated mice (Fig. 6d). Overall, MALAT1 deletion could strengthen the sensitivity response to Ox via miR-324-3p/ADAM17 axis in xenograft tumor model.

Fig. 6
figure 6

MALAT1 silencing suppressed tumor growth in Ox-resistant xenograft model mice. Sh-MALAT1 or sh-NC was injected into Ox-treated nude mice. a, b The data of the tumour image, tumor volume and weight under MALAT1 repression. c qRT-PCR analysis for the effect of MALAT1 silencing on the levels of MALAT1, miR-324-3p, and ADAM17 in tumors. d The protein level of mature ADAM17 in xenograft tumors. N = 3, *P < 0.05

Full size image

Discussion

Despite current chemotherapeutic methods evidently improved the survival of metastatic tumors, nearly all CRC patients finally developed into chemoresistance with cell metastasis [5]. Understanding the regulatory mechanism of chemoresistance in CRC is utterly important to find the therapeutic strategies for CRC [24]. MALAT1 was firstly reported to be involved in the metastatic development in non-small cell lung cancer [25], and the role of MALAT1 in CRC attracted more attentions recently [16, 26]. MALAT1 has been reported to participate in mountainous biological processes, such as development and metastatic outcomes [27]. In a previous study, the high expression of MALAT1 acted as a poor prognostic biomarker in CRC [28]. In this paper, we focused on the function of MALAT1 in Ox-resistance of CRC. The DNA damage responses acted as the pivotal functions in tumorigenesis and chemoresistance, Ox led to cell apoptosis by stimulating DNA damages [29]. Hence, it was necessary to shed light on the Ox-resistant CRC. Firstly, we found that MALAT1 was highly expressed in Ox-resistant CRC tissues and in established Ox-resistant CRC cells. The high expression of MALAT1 might be inversely associated with Ox-resistance. Moreover, knockdown of MALAT1 could notably decline the IC50 of Ox and inhibit cell proliferation, migration, EMT and promote cell apoptosis in Ox-resistant HCT116 and HCT8 cells. Moreover, MALAT1 knockdown suppressed tumor growth in Ox-treated nude mice. After elucidating the clinical value of MALAT1 in CRC, we tried to clarify the underlying molecular of MALAT1 regulating this Ox-sensitivity and unravel the probable mechanisms on the resistant evolution of CRC. Over the past decades, the interrelation between lncRNAs and miRNAs has been widely acknowledged [30]. According to the previous descriptions, starBase v3.0 software was used to predict the potential targets of MALAT1. As predicted by TargetScan7.2, miR-324-3p was found to be a candidate target of MALAT1. A previous research exposed that miR-324-3p functioned as a distinct biological role in human cancers [31]. MiR-324-3p could modulate the progression of cholangiocarcinoma through targeting ATP-binding cassette transporter A1 [32]. Collectively, miR-324-5p acted as a tumor suppressor in mountainous cancers, including CRC. Moreover, miR-324-5p was tightly associated with cisplatin resistance in non-small cell lung cancer cells [33]. Hence, we explored whether miR-324-3p could participate in the resistant response in CRC. Subsequently, low expression of miR-324-3p was observed, which was involved in the resistance of Ox-resistant CRC cells. Furthermore, miR-324-3p inhibitor could regain the effect of MALAT1 silencing on Ox-resistance in vitro. All findings illuminated that miR-324-3p, a target of MALAT1, was implicated in the Ox-sensitivity in CRC.

Previous studies also validated that miRNA could bind to the 3′UTR of mRNA [34]. In this paper, ADAM17 was predicted to be a target of miR-324-3p by TargetScan7.2. ADAM17 was a key mediator of chemoresistance in HCT116 cells, and its promoting effect on tumor growth was also discovered in previous research [35]. The deletion of ADAM17 specially reduced the secretion of EMT-related cytokine in colon cancer [36]. Taken together, ADAM17 was an essential factor in regulating drug-resistance and cell metastasis of human cancer. In this study, ADAM17 could abolish the regulatory effects of MALAT1 deletion on Ox-sensitivity in Ox-resistant HCT116 and HCT8 cells. These findings indicated that ADAM17 functioned as a promotor in Ox-resistance in vitro.

Conclusion

In summary, high expression levels of MALAT1 and ADAM17, and low level of miR-324-3p were observed in Ox-resistant CRC tissues and cells. MALAT1 deficiency could accelerate Ox-sensitivity in HCT116/OxR and HCT8/OxR cells, while miR-324-5p reduction or ADAM17 up regulation could reverse this effect. More importantly, MALAT1 exerted promotion effect on Ox-resistance via miR-324-3p/ADAM17 axis in vitro and in vivo. MALAT1 might serve as a novel biomarker in Ox-resistant CRC patients. Nevertheless, the further explorations were needed in the further.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

References

  1. Han D, Wang M, Ma N, Xu Y, Jiang Y, Gao X. Long noncoding RNAs: novel players in colorectal cancer. Cancer Lett. 2015;361(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  2. Li PL, Zhang X, Wang LL, Du LT, Yang YM, Li J, Wang CX. MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis. 2015;36(12):1484–93.

    CAS  PubMed  Google Scholar 

  3. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12(14 Pt 1):4147–53.

    Article  CAS  PubMed  Google Scholar 

  4. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243–9.

    Article  CAS  PubMed  Google Scholar 

  5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.

    Article  CAS  PubMed  Google Scholar 

  6. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.

    Article  CAS  PubMed  Google Scholar 

  7. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.

    Article  CAS  PubMed  Google Scholar 

  8. Kornienko AE, Guenzl PM, Barlow DP, Pauler FM. Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013;11:59.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tomasoni S, Benigni A. Post-transcriptional gene regulation makes things clearer in renal fibrosis. J Am Soc Nephrol. 2013;24(7):1026–8.

    Article  CAS  PubMed  Google Scholar 

  10. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14(11):699–712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Schmitt AM, Chang HY. Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016;29(4):452–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26(6):851–8.

    Article  CAS  PubMed  Google Scholar 

  13. Guo F, Li Y, Liu Y, Wang J, Li Y, Li G. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin. 2010;42(3):224–9.

    Article  CAS  PubMed  Google Scholar 

  14. Tian X, Xu G. Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis. BMJ Open. 2015;5(9):e008653.

    Article  PubMed  PubMed Central  Google Scholar 

  15. YiRen H, YingCong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C, Ende C, XiZhou L, Yanfan C. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Molecular cancer. 2017;16(1):174.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, Sui H, Tang Y, Wang Y, Liu N, et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer. 2014;111(4):736–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Li P, Zhang X, Wang H, Wang L, Liu T, Du L, Yang Y, Wang C. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16(4):739–51.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang Y, Zheng L, Huang J, Gao F, Lin X, He L, Li D, Li Z, Ding Y, Chen L. MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS ONE. 2014;9(4):e93917.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Cortes-Sempere M, Ibanez de Caceres I. MicroRNAs as novel epigenetic biomarkers for human cancer. Clin Transl Oncol. 2011;13(6):357–62.

    Article  CAS  PubMed  Google Scholar 

  20. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS ONE. 2012;7(6):e40021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Xu J, Ai Q, Cao H, Liu Q. MiR-185-3p and miR-324-3p predict radiosensitivity of nasopharyngeal carcinoma and modulate cancer cell growth and apoptosis by targeting SMAD7. Med Sci Monit. 2015;21:2828–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Li G, Liu Y, Su Z, Ren S, Zhu G, Tian Y, Qiu Y. MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B. Eur J Cancer. 2013;49(11):2596–607.

    Article  CAS  PubMed  Google Scholar 

  23. Zhao Y, Liu Y, Lin L, Huang Q, He W, Zhang S, Dong S, Wen Z, Rao J, Liao W, et al. The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1. Mol Cancer. 2018;17(1):69.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009;69(5):1951–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–41.

    Article  PubMed  Google Scholar 

  26. Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L, Sun J, Cai J, Qin J, Ren J, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/beta-catenin signal pathway. PLoS ONE. 2013;8(11):e78700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, Ishii N, Dahiya R. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75(7):1322–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014;7(6):3174–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864–70.

    Article  CAS  PubMed  Google Scholar 

  30. Ballantyne MD, McDonald RA, Baker AH. lncRNA/MicroRNA interactions in the vasculature. Clin Pharmacol Ther. 2016;99(5):494–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kuo WT, Yu SY, Li SC, Lam HC, Chang HT, Chen WS, Yeh CY, Hung SF, Liu TC, Wu T, et al. MicroRNA-324 in human cancer: miR-324-5p and miR-324-3p have distinct biological functions in human cancer. Anticancer Res. 2016;36(10):5189–96.

    Article  CAS  PubMed  Google Scholar 

  32. Zhang B, Zhou M, Zou L, Miao J, Wang Y, Li Y, Lu S, Yu J. Long non-coding RNA LOXL1-AS1 acts as a ceRNA for miR-324-3p to contribute to cholangiocarcinoma progression via modulation of ATP-binding cassette transporter A1. Biochem Biophys Res Commun. 2019;513(4):827–33.

    Article  CAS  PubMed  Google Scholar 

  33. Ba Z, Zhou Y, Yang Z, Xu J, Zhang X. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells. J Biochem. 2019;166(6):517–27.

    Article  CAS  PubMed  Google Scholar 

  34. Muniategui A, Nogales-Cadenas R, Vazquez M, Aranguren XL, Agirre X, Luttun A, Prosper F, Pascual-Montano A, Rubio A. Quantification of miRNA-mRNA interactions. PLoS ONE. 2012;7(2):e30766.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res. 2010;16(13):3378–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Park GB, Chung YH, Kim D. 2-Deoxy-d-glucose suppresses the migration and reverses the drug resistance of colon cancer cells through ADAM expression regulation. Anticancer Drugs. 2017;28(4):410–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Abdominal Surgery, Linyi Cancer Hospital, No. 6 Lingyuan East Road, Linyi, 276001, Shandong, China

    Changru Fan, Qiulan Yuan, Guifeng Liu, Yuliang Zhang, Maojun Yan, Qingxu Sun & Chaoyu Zhu

Authors
  1. Changru Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiulan Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guifeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuliang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maojun Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qingxu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chaoyu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CF and CZ conceived and designed the experiments; QY and GL performed the experiments, Funding acquisition; YZ and MY contributed reagents/materials/analysis tools; QS wrote the paper. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Chaoyu Zhu.

Ethics declarations

Ethics approval and consent to participate

Tumor response was verified in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Besides, written informed consents were gained from all participators based on the guidelines authorized by the Ethics Committee of Linyi Cancer Hospital. This experiment was performed according to the guidelines of the National Animal Care and Ethics Institution and approved by the Animal Research Committee of Linyi Cancer Hospital.

Consent for publication

Informed consent was obtained from all patients.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Fig. S1.

MALAT1-miRNAs and miR-324-3p-mRNAs interactions are predicted using StarBase and TargetScan7.2 software. (A) Dual-luciferase reporter was detected to analyze the regulatory relationships between miRNAs and MALAT1. (B) Dual-luciferase reporter was detected to analyze the regulatory relationships between mRNAs and miR-324-3p. N = 3, *P < 0.05, **P < 0.01, ***P < 0.001.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fan, C., Yuan, Q., Liu, G. et al. Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p/ADAM17 axis in colorectal cancer cells. Cancer Cell Int 20, 473 (2020). https://doi.org/10.1186/s12935-020-01549-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-020-01549-5

Keywords

Cancer Cell International

ISSN: 1475-2867

Contact us